A novel intravitreal axitinib hydrogel demonstrated durable disease control in patients with treatment-naive neovascular age-related macular degeneration (AMD), with superior maintenance of visual ...
ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
4FRONT-1, the first 4D-150 wet AMD phase 3 trial, is being conducted in North America in treatment-naïve patients with an ...
-- More than half of patients free of injection at median follow-up of 1.7 years at 2 x 10^11 vg/eye -- “We have now followed all wet AMD patients in the OPTIC trial for a minimum of a year, and in ...
Patients with neovascular age‑related macular degeneration (AMD) whose retinal fluid cleared within 12 weeks of starting faricimab were more likely to have longer intervals between injections later in ...
Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision ...
NEW ORLEANS -- Two poster sessions that spanned 4 days of the American Academy of Ophthalmology meeting provided new data about the natural history and management of age-related macular degeneration ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Nonpersistence was defined as a treatment gap of more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results